title: A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells.
abstract: Cross-linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine-activated killer (LAK) cells with cancer-specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody-conjugated LAK cells showed specifically enhanced killing activities against anti-tumor antibody-reactive cancer cells, and cold target cells specifically inhibited their activities.
authors.affiliation: National Cancer Center Research Institute, National Cancer Center Hospital, Tokyo.
authors.forename: H
authors.initials: H
authors.lastname: Shiraiwa
authors.forename: T
authors.initials: T
authors.lastname: Sekine
authors.forename: K
authors.initials: K
authors.lastname: Tobisu
authors.forename: T
authors.initials: T
authors.lastname: Kakizoe
authors.forename: K
authors.initials: K
authors.lastname: Koiso
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007700:Kinetics; D013274:Stomach Neoplasms / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal